Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.56 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084283 | 0.83 | SLC6A4 (0.64) | SLC6A4HTR1A | |
| SCHEMBL13226846 | 0.83 | SLC6A4 (0.63) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL29005985 | 0.82 | SLC6A4 (0.62) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL15587215 | 0.82 | SLC6A4 (0.63) | SLC6A4HTR1A | |
| SCHEMBL28481587 | 0.81 | SLC6A4 (0.52) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL24328228 | 0.80 | SLC6A4 (0.59) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL29985571 | 0.80 | SLC6A4 (0.59) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL24688682 | 0.80 | SLC6A4 (0.59) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL4485828 | 0.78 | TSHR (0.64) | SLC6A4DRD2DRD4DRD3 | |
| SCHEMBL8136598 | 0.77 | SLC6A4 (0.64) | SLC6A4DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104418842-B | Substituted benzazolyl compounds and its application method and purposes | 广东东阳光药业有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-9714232-B2 | Substituted piperazine compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| CN-104725359-B | Substituted piperazine compound as well as application method and application thereof | 广东东阳光药业有限公司 | 2017-05-03 | — | — | CN | disclosed |
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| CN-104725359-A | Substituted piperazine compound as well as application method and application thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-06-24 | — | — | CN | disclosed |
| CN-104418842-A | Substituted indole compound and using method and application thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | HTR5A, HTR2A, HTR2C | SLC6A4 19/4885DRD2 88/4885DRD4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.